Epinephrine
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | NEFFY | — | 2025-03-05 – 2026-03-26 | fda.gov ↗ |
| Approved | EU (EMA) | Eurneffy | — | 2024-08-22 | europa.eu ↗ |
| Label expansion | US (FDA) | ADRENALIN | — | 2019-01-29 | fda.gov ↗ |
| Label expansion | US (FDA) | SYMJEPI | — | 2018-09-27 | fda.gov ↗ |
| Label expansion | US (FDA) | AUVI-Q | — | 2017-11-17 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | EPINEPHRINE | — | 2015-10-23 – 2016-02-11 | fda.gov ↗ |
| Label expansion | US (FDA) | SUS-PHRINE SULFITE FREE | — | 2007-12-07 | fda.gov ↗ |
| Label expansion | US (FDA) | ADRENACLICK | — | 2004-05-28 | fda.gov ↗ |
| Approved | US (FDA) | XYLOCAINE DENTAL WITH EPINEPHRINE | — | 1948-11-19 | fda.gov ↗ |
Trials 209 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06416969 | Jan 2024 → Jan 2028 expected | obesity disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT04148261 | Dec 2020 → Dec 2022 | depressive disorder | Stanford University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04019834 | Jul 2020 → Nov 2021 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT05037812 | Mar 2019 → Mar 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02692313 | Jun 2016 → Sep 2025 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT07038746 | Aug 2025 → Jun 2026 overdue | anaphylaxis | Dr. George Luciuk | Recruiting | No outcome recorded |
| Phase 1 | NCT07703982 | Dec 2024 → Mar 2025 | hypersensitivity reaction disease | Aquestive Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06445374 | Jul 2024 → Apr 2025 | anaphylaxis | Dr. George Luciuk | Completed | No outcome recorded |
| Phase 1 | NCT06013150 | Oct → Dec 2023 | anaphylaxis | De Motu Cordis | Completed | No outcome recorded |
| Phase 1 | NCT05670808 | Feb → Jun 2023 | — | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT05986266 | Feb → Aug 2023 | uterine benign neoplasm | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT05062356 | Nov 2021 → Aug 2024 | chronic pain syndrome | St. Mary's Research Center, Canada | Completed | No outcome recorded |
| Phase 1 | NCT04696822 | Nov 2020 → Sep 2021 | anaphylaxis | Nasus Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03441412 | Feb → Mar 2018 | — | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 1 | NCT03399435 | Jan → Sep 2018 | — | Grünenthal GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT03282929 | Mar 2017 → Sep 2018 | anaphylaxis | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT04551703 | Jul 2016 → Aug 2020 | chronic rhinosinusitis | Jordan University of Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT01032798 | May 2007 → May 2008 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07228325 | Nov 2025 → Mar 2026 overdue | allergic disease, anaphylaxis | Nasus Pharma | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06447194 | Oct 2025 → Jan 2027 | intervertebral disk degenerative disorder, lumbar spinal stenosis, spondylolisthesis | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06205134 | Aug 2023 → Feb 2024 | anaphylaxis | Nasus Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT03970655 | Sep 2019 → Jan 2026 overdue | chronic rhinosinusitis | University of Florida | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03780478 | Jun 2019 → Dec 2021 | — | University of Southern California | Unknown | No outcome recorded |
| Phase 1/2 | NCT01188577 | Aug → Sep 2010 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01143051 | Jan → Jun 2010 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01025648 | Dec 2009 | asthma | Amphastar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00977028 | Jan 2005 → Jul 2011 | — | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06270147 | Nov 2024 → Jan 2025 overdue | substance-related disorder | McMaster University | Recruiting | No outcome recorded |
| Phase 2 | NCT06478797 | Jul 2024 → Jul 2025 | infectious disease with sepsis | NATALIA LOPERA MUNERA | Unknown | No outcome recorded |
| Phase 2 | NCT06789549 | Jan → Mar 2024 | — | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT05355597 | Jan 2021 → Mar 2025 | musculoskeletal system disorder, soft tissue neoplasm | Atlantic Health System | Terminated | No outcome recorded |
| Phase 2 | NCT05324995 | Jan 2021 → Feb 2022 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03865147 | Jan → Jul 2019 | — | Medical Ethics UK Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT03549221 | Jan → Oct 2018 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT02585531 | Nov 2015 → Feb 2017 | bronchiolitis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 2 | NCT02591771 | Oct 2015 → Jul 2017 | cardiogenic shock | Niguarda Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01202487 | Apr 2011 → Jan 2012 | — | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 2 | NCT01255709 | Dec 2010 → Jan 2011 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00980616 | Sep 2009 → Sep 2010 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 2 | NCT00678145 | Mar 2008 → Aug 2018 | autonomic nervous system disorder, hypoglycemia, type 1 diabetes mellitus | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00121524 | Jan 2003 → May 2008 | cardiac arrest | Petter Andreas Steen | Completed | No outcome recorded |
| Phase 2 | NCT00134212 | Mar 2002 → Jun 2004 | infectious disease with sepsis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07045701 | Jun 2025 → Jun 2026 overdue | food allergy | Nasus Pharma | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT06456255 | Nov 2024 → May 2025 overdue | hemorrhagic disease, paranasal sinus disorder | Amin Javer | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06519955 | Oct 2024 → May 2026 overdue | developmental dysplasia of the hip | Michael C Willey | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05166343 | Jan 2024 → Jan 2028 expected | post-cardiac arrest syndrome | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03408483 | Apr 2018 → May 2019 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2/3 | NCT03126968 | Jul 2017 → Jul 2021 | hemorrhagic disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2/3 | NCT02586961 | Oct 2015 → Sep 2017 | acute bronchiolitis | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 2/3 | NCT02453516 | Oct 2014 → Sep 2019 | — | Women's College Hospital | Completed | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT07442071 | Jun 2026 → Jul 2030 expected | cardiac arrest | Central Hospital, Nancy, France | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06264596 | Aug 2024 → Aug 2025 | esophageal varices with bleeding | The Guthrie Clinic | Withdrawn | No outcome recorded |
| Phase 3 | NCT06381622 | Apr → Oct 2024 | — | Nordsjaellands Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05191745 | Jan 2022 → Apr 2023 | — | Jewish General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04750070 | Aug 2021 → Jul 2025 overdue | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Recruiting | No outcome recorded |
| Phase 3 | NCT04850885 | Aug 2020 → Feb 2021 | — | Tribhuvan University, Nepal | Completed | No outcome recorded |
| Phase 3 | NCT04032119 | Jan 2020 → Dec 2022 | gastric carcinoma | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT03567473 | Dec 2018 → Jan 2025 | bronchiolitis | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 3 | NCT03513445 | Jun 2018 → Mar 2022 | intervertebral disk degenerative disorder, lumbar disk disease, spondylolisthesis | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 3 | NCT02740127 | Jun 2016 → May 2020 | male reproductive organ cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02540070 | Aug 2014 → Dec 2017 | osteoarthritis, knee | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT02568995 | May 2014 → Sep 2016 | — | Örebro University, Sweden | Completed | No outcome recorded |
| Phase 3 | NCT02112370 | May 2014 → May 2016 | goiter, thyroid tumor | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01861015 | May 2013 → Mar 2014 | leiomyoma | CHA University | Completed | No outcome recorded |
| Phase 3 | NCT01708642 | Nov 2012 → Sep 2013 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT01737905 | Oct 2012 → Mar 2013 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01476904 | Nov 2011 → Apr 2012 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01357642 | Jul → Nov 2011 | asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00446017 | Jun 2003 → Aug 2004 | heart failure | University of Luebeck | Completed | No outcome recorded |
| Phase 3 | NCT00002659 | May 1995 → ? | head and neck cancer | Matrix Pharmaceutical | Unknown | No outcome recorded |
| Phase 469 trials | ||||||
| Phase 4 | NCT07089251 | Jul 2025 → Jun 2027 expected | osteoarthritis, knee | King Abdullah International Medical Research Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05972681 | Apr → Oct 2025 | — | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT07425678 | Jan → Jul 2025 | supratentorial cancer | Aga Khan University | Completed | No outcome recorded |
| Phase 4 | NCT07006168 | Nov 2024 → Dec 2026 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT05996133 | Dec 2023 → Dec 2026 expected | — | Hartford Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06189781 | Dec 2023 → Dec 2026 expected | cerebral palsy, developmental dysplasia of the hip | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 4 | NCT06113497 | Nov 2023 → Oct 2024 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05667727 | Oct 2023 → Jun 2025 | childhood onset asthma | Oman Medical Speciality Board | Completed | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05492968 | Sep 2022 → Aug 2024 | high output heart failure | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT05244525 | Mar → Aug 2022 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT05029726 | Feb 2022 → Feb 2027 expected | ganglion or cyst of synovium/tendon/bursa, intervertebral disk degenerative disorder, lumbar disk disease, lumbar spinal stenosis +3 | John O'Toole | Recruiting | No outcome recorded |
| Phase 4 | NCT05292677 | Jul 2021 → Jun 2023 | laryngeal disorder | Eastern Virginia Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT05413902 | Apr 2021 → Jan 2022 | — | University of Puerto Rico | Completed | No outcome recorded |
| Phase 4 | NCT07480135 | Apr → May 2021 | — | Vrije Universiteit Brussel | Completed | No outcome recorded |
| Phase 4 | NCT04699110 | Jan → Apr 2021 | acute coronary syndrome | National Institute of Cardiovascular Diseases, Pakistan | Completed | No outcome recorded |
| Phase 4 | NCT03696199 | Sep 2020 → Sep 2026 expected | — | Lahey Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT04065451 | Jan 2020 → Aug 2021 | polyp of colon | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT04207840 | Dec 2019 | anaphylaxis, asthma | Amphastar Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03335293 | Oct → Dec 2019 | pregnancy disorder | University of Florida | Withdrawn | No outcome recorded |
| Phase 4 | NCT03794882 | May 2019 → Mar 2020 | neuropathy, painful, substance-related disorder | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 4 | NCT03906617 | Apr 2019 → Apr 2022 overdue | — | The Cooper Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT04799184 | Apr 2019 → Aug 2021 | local anesthetic poisoning | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT03638726 | Sep 2018 → Mar 2019 | cataract | Dar El Oyoun Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03368391 | Jan → Jun 2018 | dental pulp disorder, local anesthetic poisoning | Louisiana State University Health Sciences Center in New Orleans | Unknown | No outcome recorded |
| Phase 4 | NCT03071601 | Dec 2017 → Dec 2021 | — | Centre Hospitalier le Mans | Completed | No outcome recorded |
| Phase 4 | NCT03366298 | Nov 2017 → Oct 2018 | anaphylaxis | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT03198403 | Aug → Sep 2017 | — | Regionshospitalet Silkeborg | Completed | No outcome recorded |
| Phase 4 | NCT03862404 | Jul 2017 → Feb 2019 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 4 | NCT04203225 | May 2017 → Nov 2019 | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05867342 | May 2017 → Aug 2018 | esophageal varices with bleeding | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03105674 | May → Nov 2017 | anal fistula, hemorrhoid, ulcer of anus and rectum | Columbia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT03279757 | Oct → Dec 2016 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02967172 | Oct 2016 → Sep 2018 | ankle defects short stature, neuropathy, painful | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT02980835 | Sep 2016 → Mar 2022 | — | University at Buffalo | Completed | No outcome recorded |
| Phase 4 | NCT02839356 | Jul 2016 → Dec 2017 | acute pancreatitis | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02697955 | Jun 2016 → Feb 2017 | osteoarthritis | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT02938286 | Mar → Aug 2016 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT03513276 | Feb 2016 → Feb 2018 | osteoarthritis, hip | Hospital Mutua de Terrassa | Completed | No outcome recorded |
| Phase 4 | NCT02570503 | Oct 2015 → Feb 2021 | osteoarthritis, knee | Virginia Commonwealth University | Terminated | No outcome recorded |
| Phase 4 | NCT02571283 | Oct 2015 → May 2016 | — | University of Louisville | Withdrawn | No outcome recorded |
| Phase 4 | NCT02474654 | Jul 2015 → Jan 2019 | — | Health Sciences North Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02548533 | Jun 2015 → Jan 2016 | — | Netherlands Institute for Pigment Disorders | Terminated | No outcome recorded |
| Phase 4 | NCT02793947 | May 2015 → Aug 2016 | neuropathy, painful | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT02365727 | Apr → Aug 2015 | osteoarthritis, knee | The Hawkins Foundation | Withdrawn | No outcome recorded |
| Phase 4 | NCT02369510 | Feb 2015 → May 2016 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT02696369 | Dec 2014 → Aug 2015 | impacted teeth, multiple | Huons Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02735018 | Dec 2014 → Mar 2015 | — | Rio de Janeiro State University | Completed | No outcome recorded |
| Phase 4 | NCT02246179 | Sep → Oct 2014 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT02274974 | Aug 2014 → Mar 2015 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02270437 | Jun 2014 → Aug 2015 | — | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01964781 | Aug 2013 → Dec 2014 | neuropathy, painful | St. Olavs Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01705964 | Jun 2013 → Apr 2018 | asthma | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT01834820 | Jan 2013 → Jun 2015 | bronchiolitis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Completed | No outcome recorded |
| Phase 4 | NCT01706952 | Dec 2012 → Dec 2013 | chronic rhinosinusitis | Marc Tewfik | Completed | No outcome recorded |
| Phase 4 | NCT05439460 | Jan 2012 → Jun 2014 | pulmonary arterial hypertension | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01596998 | Dec 2011 → Apr 2012 | — | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT01756443 | Aug 2011 → Dec 2012 | — | Cork University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01243112 | May → Sep 2010 | — | Scott and White Hospital & Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01281891 | Sep 2009 → Sep 2012 | osteoarthritis, hip | Region Örebro County | Unknown | No outcome recorded |
| Phase 4 | NCT01418118 | Oct 2008 → Feb 2010 | head and neck cancer, hypotensive disorder, oral cavity cancer | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT00685672 | Aug 2008 → Jan 2016 | pain agnosia, pregnancy disorder | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00901628 | Apr 2008 → Mar 2009 | osteoarthritis, knee | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00421967 | Jan 2007 → Mar 2008 | osteoarthritis, knee | University of Aarhus | Terminated | No outcome recorded |
| Phase 4 | NCT00318292 | Apr 2006 → Mar 2008 | neuropathy, painful | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00270777 | Mar 2005 → Apr 2008 | snakebite envenomation | University of Kelaniya | Completed | No outcome recorded |
| Phase 4 | NCT00289419 | Feb 2005 → Feb 2006 | osteoarthritis, hip | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00127907 | May 2004 → Oct 2007 | cardiac arrest | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT00361452 | Dec 2000 → May 2001 | respiratory syncytial virus bronchiolitis | Rambam Health Care Campus | Terminated | No outcome recorded |
| Phase not applicable70 trials | ||||||
| — | NCT07667829 | Jun 2026 → Dec 2028 expected | chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT07604337 | Jun → Dec 2026 expected | delirium | seher orbay yasli | Not yet recruiting | No outcome recorded |
| — | NCT07633106 | Feb → Jul 2026 overdue | glucose metabolism disease | Dow University of Health Sciences | Active not recruiting | No outcome recorded |
| — | NCT07349407 | Dec 2025 → Nov 2026 expected | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07084753 | Jul → Sep 2025 overdue | obesity disorder | IVO JURISIC | Not yet recruiting | No outcome recorded |
| — | NCT07273526 | Jun → Dec 2025 overdue | infectious disease with sepsis | Laiba Qamar | Recruiting | No outcome recorded |
| — | NCT07436546 | Mar → Dec 2025 | impacted teeth, multiple | Postgraduate Institute of Dental Sciences Rohtak | Completed | No outcome recorded |
| — | NCT06566352 | May 2024 → May 2025 overdue | — | Zagazig University | Recruiting | No outcome recorded |
| — | NCT06112548 | Mar 2024 → Nov 2025 | osteoarthritis, knee | Damascus University | Completed | No outcome recorded |
| — | NCT06172400 | Jan → Dec 2024 | carpal tunnel syndrome | Region Skane | Unknown | No outcome recorded |
| — | NCT06145191 | Dec 2023 → Mar 2025 | hemorrhagic disease | Clinical Hospital Centre Zagreb | Completed | No outcome recorded |
| — | NCT05990933 | Dec 2023 → Sep 2024 | hypoglycemia, inflammatory disease, type 1 diabetes mellitus | Cees Tack | Completed | No outcome recorded |
| — | NCT05908851 | Nov 2023 → Nov 2024 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| — | NCT06896409 | Oct 2023 → Oct 2025 overdue | — | Tallaght University Hospital | Recruiting | No outcome recorded |
| — | NCT05943080 | Jun → Aug 2023 | osteoarthritis, knee | Kirsehir Ahi Evran Universitesi | Completed | No outcome recorded |
| — | NCT06030479 | Feb → Oct 2023 | placenta accreta, placenta praevia | Cairo University | Unknown | No outcome recorded |
| — | NCT05534945 | Dec 2022 → Jul 2026 overdue | — | Ciusss de L'Est de l'Île de Montréal | Recruiting | No outcome recorded |
| — | NCT05439213 | Jun 2022 → Jun 2023 | rotator cuff syndrome | Ramsay Santé | Completed | No outcome recorded |
| — | NCT05406895 | May 2022 → Mar 2024 | — | Louisiana State University Health Sciences Center in New Orleans | Completed | No outcome recorded |
| — | NCT05728151 | Feb 2022 → Apr 2024 | strabismus | Research Institute of Ophthalmology, Egypt | Completed | No outcome recorded |
| — | NCT04773405 | Mar → Nov 2021 | musculoskeletal system disorder | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT04282239 | Mar → Dec 2021 | — | NYU Langone Health | Withdrawn | No outcome recorded |
| — | NCT04771923 | Feb 2021 → Feb 2022 | hemorrhagic disease | Clinical Hospital Centre Zagreb | Completed | No outcome recorded |
| — | NCT04494100 | Sep 2020 → Jun 2021 | carpal tunnel syndrome | CMC Ambroise Paré | Completed | No outcome recorded |
| — | NCT04562103 | Jul → Aug 2020 | local anesthetic poisoning | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| — | NCT05095259 | Dec 2019 → Dec 2023 | type 1 diabetes mellitus | Nordsjaellands Hospital | Unknown | No outcome recorded |
| — | NCT04131283 | May → Dec 2019 | gingival disorder | Semmelweis University | Completed | No outcome recorded |
| — | NCT03814954 | Jan 2019 → Aug 2021 | — | Makassed General Hospital | Completed | No outcome recorded |
| — | NCT03693820 | Sep 2018 → Jun 2019 | — | Alaa Mazy Mazy | Completed | No outcome recorded |
| — | NCT04029610 | Aug 2018 → Dec 2019 | — | Uri farkash | Completed | No outcome recorded |
| — | NCT03914235 | Aug 2018 → Mar 2019 | tenosynovitis | Mexican Social Security Institute | Completed | No outcome recorded |
| — | NCT03427502 | Jun 2018 → Dec 2019 | anterior deviation infundibular septum, chronic rhinosinusitis, nasal cavity polyp | Lumbini Medical College | Completed | No outcome recorded |
| — | NCT03395912 | Jan 2018 → May 2020 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT05248724 | Aug 2017 → Sep 2020 | — | Castilla-La Mancha Health Service | Completed | No outcome recorded |
| — | NCT03135340 | Aug 2017 → Nov 2018 overdue | — | University of Western Ontario, Canada | Not yet recruiting | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT03319563 | Apr → Oct 2017 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT03057769 | Feb → Oct 2017 | pancreatitis | Air Force Military Medical University, China | Terminated | No outcome recorded |
| — | NCT04628676 | Feb 2017 → Dec 2019 | rotator cuff syndrome | Haseki Training and Research Hospital | Completed | No outcome recorded |
| — | NCT01911949 | Jan → Aug 2017 | — | McMaster University | Completed | No outcome recorded |
| — | NCT02909140 | Sep 2016 → Aug 2018 | cataract | Johns Hopkins University | Terminated | No outcome recorded |
| — | NCT04378283 | May 2016 → Feb 2020 | — | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT02505633 | Jul → Sep 2015 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| — | NCT02864095 | May 2015 → Oct 2017 | — | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT02860221 | May 2015 → Jul 2017 | — | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT02422823 | Apr 2015 → Jun 2016 | pulpitis | Isabel Peixoto Tortamano | Completed | No outcome recorded |
| — | NCT02285634 | Nov 2014 → Dec 2016 | hypertensive disorder | Mayo Clinic | Completed | No outcome recorded |
| — | NCT02228083 | Sep 2014 → Sep 2016 | heart failure | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT02379221 | Sep 2014 → Mar 2016 | — | David Grant U.S. Air Force Medical Center | Completed | No outcome recorded |
| — | NCT02104778 | Apr 2014 → Jun 2016 | — | Yeungnam University College of Medicine | Unknown | No outcome recorded |
| — | NCT04153123 | Dec 2013 → May 2014 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| — | NCT01800877 | Apr 2013 → Dec 2014 | hypotensive disorder | Francois Lamontagne | Completed | No outcome recorded |
| — | NCT02268019 | Jan 2013 → Jan 2015 | hypospadias | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01497509 | May → Nov 2012 | — | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| — | NCT01560702 | Mar 2012 → Sep 2013 | peptic ulcer disease | Zagazig University | Completed | No outcome recorded |
| — | NCT01264653 | Dec 2010 → Dec 2011 | cataract | Wenzhou Medical University | Completed | No outcome recorded |
| — | NCT01432522 | Jul 2010 → Aug 2011 | anaphylaxis | Siriraj Hospital | Completed | No outcome recorded |
| — | NCT01131741 | May → Jul 2010 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT01075581 | Apr 2010 → Apr 2011 | cardiac rhythm disease, essential hypertension, hypotensive disorder | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01080625 | Apr 2010 → Sep 2011 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT01264575 | Dec 2009 → Jan 2011 | — | Seoul Medical Center | Completed | No outcome recorded |
| — | NCT00523055 | May 2008 → Apr 2012 | — | University of Manitoba | Terminated | No outcome recorded |
| — | NCT00548886 | Feb 2008 → Jan 2012 | — | Emory University | Terminated | No outcome recorded |
| — | NCT00322660 | Jun 2006 → Jun 2007 | hypoglycemia, respiratory failure | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT00225043 | Jun 2005 → Aug 2007 | — | New York Presbyterian Brooklyn Methodist Hospital | Completed | No outcome recorded |
| — | NCT01116609 | Oct 2004 → Nov 2009 | — | University of Aarhus | Completed | No outcome recorded |
| — | NCT00114478 | Nov 2003 → May 2006 | bronchiolitis | Kern Medical Center | Unknown | No outcome recorded |
| — | NCT01513564 | Jan 2001 → Dec 2003 | spondylolisthesis | Northern Orthopaedic Division, Denmark | Completed | No outcome recorded |
| — | NCT00608816 | — | type 1 diabetes mellitus | Vanderbilt University | Withdrawn | No outcome recorded |
| — | NCT00605774 | — | type 1 diabetes mellitus | Vanderbilt University | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 400 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 013 trials | ||||||
| Phase 0 | NCT06345833 Background | Jul 2024 → Jul 2026 overdue | hemophilia, hemorrhagic disease | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT06149091 Comparator | Dec 2023 → Dec 2024 | bronchial disorder | China-Japan Friendship Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04630886 Background | Jun 2021 → Jan 2024 | skin neoplasm | Riley McLean | Terminated | No outcome recorded |
| Phase 0 | NCT05019638 Comparator | Mar 2021 → May 2028 expected | — | University of Utah | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04263064 Comparator | Mar 2020 → Aug 2022 | — | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 0 | NCT03388814 Background | Nov 2018 → Jun 2020 | breast cancer, neuropathy, painful, substance-related disorder | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT06499181 Comparator | Feb 2018 → Jan 2020 | neuropathy, painful | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT03243032 Background | Oct → Nov 2017 | neuropathy, painful | Satheesh Elangovan | Withdrawn | No outcome recorded |
| Phase 0 | NCT02991404 Background | Feb → Nov 2017 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03070054 Background | Jun 2016 → Mar 2020 | — | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT02831374 Background | Oct 2015 → Mar 2016 | impacted teeth, multiple | Linyi People's Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02319915 Comparator | Feb 2015 → Mar 2017 | — | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02369523 Comparator | Sep 2014 → Apr 2017 | — | University of Utah | Terminated | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT07210320 Comparator | Oct 2025 → Apr 2026 | anaphylaxis, food allergy | Insignis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06564987 Comparator | Jan → Dec 2024 overdue | — | Cleveland Dental Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05738148 Comparator | Nov 2023 → Jan 2026 overdue | cardiac arrest | University of Alberta | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05343299 Background | May 2022 → Jun 2023 | — | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05152901 Comparator | Jan → Jun 2022 | anaphylaxis | De Motu Cordis | Completed | No outcome recorded |
| Phase 1 | NCT05267938 Background | Aug → Oct 2019 | mouth disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT03880409 Comparator | Feb → Sep 2019 | — | Taibah University | Completed | No outcome recorded |
| Phase 1 | NCT04692896 Background | Sep 2017 → Mar 2018 | — | King Edward Medical University | Completed | No outcome recorded |
| Phase 1 | NCT03268278 Comparator | Apr 2017 → Jul 2018 | — | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02593370 Background | Oct → Nov 2015 | bone disorder | Thomas F. Bendtsen | Completed | No outcome recorded |
| Phase 1 | NCT02269735 Background | Nov 2014 → Jul 2016 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05006235 Comparator | Feb 2014 → Dec 2015 | persistent tachypnoe of infancy, usual | Ahmed Noaman | Completed | No outcome recorded |
| Phase 1 | NCT01786655 Background | May 2013 → Mar 2014 | — | Charles Berde | Completed | No outcome recorded |
| Phase 1 | NCT00753402 Comparator | Feb 2012 | immune system disorder | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1 | NCT01064986 Comparator | Feb 2010 → Dec 2012 | infectious disease | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1 | NCT00628550 Comparator | Apr 2008 → Oct 2010 | cardiac arrest | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT06820164 Background | May 2025 → Jan 2027 expected | lipoma | West Virginia University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04432597 Background | Aug 2020 → Nov 2022 overdue | anal carcinoma, cervical cancer, oropharynx cancer, virus associated tumor | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04061265 Background | Aug 2019 → Jan 2020 | — | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT03963115 Comparator | Oct 2018 → Aug 2019 | hypersensitivity reaction disease | Mahidol University | Completed | No outcome recorded |
| Phase 1/2 | NCT03554473 Background | Sep 2018 → Jun 2022 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02722746 Comparator | Nov 2016 → Oct 2017 | hypotensive disorder | University of Florida | Completed | No outcome recorded |
| Phase 1/2 | NCT02356159 Background | Sep 2015 → Dec 2024 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03560362 Comparator | Jul 2015 → Oct 2018 | lung cancer, neuropathy, painful | University of Tennessee | Unknown | No outcome recorded |
| Phase 1/2 | NCT02065947 Background | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01737892 Comparator | Nov 2012 | asthma | Amphastar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 241 trials | ||||||
| Phase 2 | NCT04414917 Background | Nov 2026 → Nov 2029 | neuropathy, painful | Rutgers, The State University of New Jersey | Suspended | No outcome recorded |
| Phase 2 | NCT07094542 Background | Sep 2026 → Nov 2029 expected | impacted teeth, multiple, myofascial pain syndrome | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07068243 Background | Sep 2026 → Feb 2027 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07518238 Comparator | Jan 2026 → Nov 2029 expected | BD syndrome | Baylor Research Institute | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06927999 Comparator | Jul 2025 → Jun 2026 overdue | chronic urticaria | ARS Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06429501 Background | Apr 2024 → Feb 2027 expected | — | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06057675 Background | Mar 2024 → Jun 2026 overdue | skin cancer | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04880707 Comparator | Mar 2024 → Aug 2026 overdue | — | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT05840913 Background | Dec 2023 → Jul 2024 | pulpitis | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 2 | NCT05327556 Comparator | Feb 2023 → May 2025 | hypotensive disorder | Boston Children's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT06862570 Background | Dec 2022 → May 2023 | pulpitis | 28 Military Dental Centre Lahore | Completed | No outcome recorded |
| Phase 2 | NCT05335070 Background | Sep 2022 → Nov 2026 expected | — | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT06532162 Background | Jun 2022 → Aug 2024 | — | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 2 | NCT04427904 Comparator | Jun 2022 → Dec 2024 | thyroid gland disorder | St. Joseph's Healthcare Hamilton | Unknown | No outcome recorded |
| Phase 2 | NCT04717193 Background | May 2021 → Apr 2023 | appendicitis | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT06784570 Comparator | Jan 2021 → Mar 2024 | left ventricular failure | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT04603911 Comparator | Dec 2020 → Apr 2023 | breast cancer | Tufts Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04339868 Comparator | Apr 2020 → Mar 2025 | infectious disease with sepsis | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT03383588 Comparator | Jul → Aug 2018 | myofascial pain syndrome | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT04947267 Comparator | May 2018 → Sep 2019 | — | Afshan Amjad Ali | Completed | No outcome recorded |
| Phase 2 | NCT03236324 Background | Sep 2017 → Oct 2022 | — | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT03197558 Background | Jun → Sep 2017 | eustachian tube disorder, otitis media with effusion | Tusker Medical | Completed | No outcome recorded |
| Phase 2 | NCT03119181 Comparator | Apr → May 2017 | — | Tusker Medical | Completed | No outcome recorded |
| Phase 2 | NCT03112135 Comparator | Apr 2017 → Jan 2018 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT03007966 Background | Jan 2017 → Feb 2018 | hernia, double inguinal | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02946294 Comparator | Oct 2016 → Dec 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT02718976 Background | Mar → Apr 2016 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT03034382 Background | Jan 2016 → May 2017 | rotator cuff syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT02525718 Comparator | Aug 2015 → Nov 2016 | breast cancer | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT02860949 Background | Apr 2014 → Apr 2015 | osteoarthritis, knee | Thammasat University | Completed | No outcome recorded |
| Phase 2 | NCT01759407 Comparator | May 2013 → Oct 2016 | bone disorder | Nationwide Children's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01878864 Comparator | Nov 2012 → Jun 2013 | periodontitis | Ove Andersen | Terminated | No outcome recorded |
| Phase 2 | NCT01794533 Comparator | Oct 2012 → Jan 2013 | pulpitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2 | NCT01405768 Background | Jul 2011 → Oct 2012 | dysplasia of cervix | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01301313 Comparator | Feb 2011 → Feb 2012 | heart failure | Jose Luis Vazquez Martinez | Terminated | No outcome recorded |
| Phase 2 | NCT01059786 Background | Jul 2010 → Dec 2022 overdue | hairy cell leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01572116 Comparator | Jan 2010 → Jun 2011 | pulpitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2 | NCT00890162 Comparator | Apr 2009 → Jul 2018 | angioedema, bronchial disorder, hypotensive disorder, idiopathic anaphylaxis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00624650 Background | Feb 2008 → Jan 2011 | acute lung injury | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT00401882 Comparator | Jan 2007 → Jun 2011 | cardiac arrest, sudden cardiac arrest, ventricular fibrillation, ventricular tachycardia | David Haines, MD | Terminated | No outcome recorded |
| Phase 2 | NCT00411879 Background | Jun 2006 → Apr 2007 | cardiac arrest | University of Athens | Completed | No outcome recorded |
| Phase 2/315 trials | ||||||
| Phase 2/3 | NCT07151417 Background | Sep 2025 → Aug 2026 overdue | osteoarthritis, knee | Walter Reed National Military Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07000058 Comparator | Jun → Dec 2025 overdue | — | Misr University for Science and Technology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06801522 Comparator | Dec 2024 → Mar 2025 overdue | — | Shaheed Mohtarma Benazir Bhutto Institue of Trauma | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05313256 Comparator | Jul 2022 → Jul 2024 | obstetric disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 2/3 | NCT03226626 Background | Dec 2021 → Jan 2022 | infectious disease with sepsis, thrombotic disease | HK Surgical, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04733781 Comparator | Feb → Jun 2021 | musculoskeletal system disorder, snakebite envenomation | Jeffrey Alan Klein, MD | Unknown | No outcome recorded |
| Phase 2/3 | NCT03730714 Comparator | Nov 2018 → Aug 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03036085 Comparator | Feb → Dec 2017 | local anesthetic poisoning, neuropathy, painful, opiate dependence | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02760043 Background | Apr 2016 → Oct 2018 | osteoarthritis | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2/3 | NCT02503904 Comparator | Oct 2015 → Jun 2019 | venous thromboembolism | Klein, Jeffrey A., M.D. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02428062 Background | Oct 2014 → Dec 2018 | — | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Suspended | No outcome recorded |
| Phase 2/3 | NCT02752308 Comparator | Sep 2014 → Mar 2015 | hypospadias | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02030717 Comparator | Feb 2012 → May 2015 | renal cell carcinoma | Umeå University | Completed | No outcome recorded |
| Phase 2/3 | NCT00298571 Background | Feb 2006 → Oct 2007 | neuropathy, painful | University of South Florida | Completed | No outcome recorded |
| Phase 2/3 | NCT00148278 Comparator | Oct 1999 → Dec 2004 | infectious disease with sepsis | University of Versailles | Completed | No outcome recorded |
| Phase 327 trials | ||||||
| Phase 3 | NCT07592143 Background | Jul → Dec 2026 expected | — | King Edward Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07480889 Comparator | Mar → May 2026 overdue | — | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07092566 Comparator | Nov 2025 → Oct 2027 expected | renal carcinoma | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06789575 Comparator | Mar 2025 → Mar 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06284434 Background | Apr 2024 → Apr 2026 overdue | cleft lip/palate | Kerry O'Rourke | Recruiting | No outcome recorded |
| Phase 3 | NCT06379490 Background | Apr 2024 → Jun 2025 | — | Nordsjaellands Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06847568 Comparator | Apr 2024 → Apr 2026 overdue | ST-elevation myocardial infarction | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT05964868 Comparator | Feb 2024 → Dec 2026 expected | — | Jessyka Lighthall | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06267118 Comparator | Nov 2023 → Nov 2024 overdue | respiratory syncytial virus bronchiolitis | Combined Military Hospital, Pakistan | Recruiting | No outcome recorded |
| Phase 3 | NCT05839548 Background | Jul 2023 → May 2025 overdue | dental caries, dental pulp disorder | Qassim Health Cluster | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05822765 Comparator | May → Oct 2023 | — | Al-Azhar University | Completed | No outcome recorded |
| Phase 3 | NCT05300685 Comparator | Feb 2022 → Jul 2026 overdue | urethral stricture | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 3 | NCT05738564 Comparator | Sep 2021 → Apr 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04477317 Background | Aug → Sep 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04255121 Background | Jun → Dec 2020 | — | Reims University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03025594 Comparator | Jan → Aug 2017 | osteoarthritis, knee | maximiliano barahona vasquez | Unknown | No outcome recorded |
| Phase 3 | NCT02741713 Comparator | Apr 2016 → Jun 2017 | bicipital tenosynovitis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02534571 Comparator | Sep 2015 → Jan 2019 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT02807298 Background | Jun → Oct 2014 | pulpitis | Dr. D. Y. Patil Dental College & Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02007434 Background | Dec 2013 → Jun 2014 | — | Kythera Biopharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02371759 Comparator | Jun 2013 → Jan 2016 | diabetes mellitus | University of Belgrade | Completed | No outcome recorded |
| Phase 3 | NCT02226913 Background | Feb → Sep 2013 | — | Masoud Saatchi | Completed | No outcome recorded |
| Phase 3 | NCT01700192 Background | Jan 2013 → Apr 2015 | perennial allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 3 | NCT01782781 Comparator | Nov 2012 → Oct 2014 | — | Göteborg University | Completed | No outcome recorded |
| Phase 3 | NCT00852410 Comparator | Mar 2009 → Apr 2010 | chronic rhinosinusitis | University of Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT00729794 Comparator | Sep 2008 → Nov 2010 | cardiac arrest | University of Athens | Completed | No outcome recorded |
| Phase 3 | NCT00358579 Comparator | Mar 2006 → Jan 2009 | cardiac arrest | Singapore General Hospital | Completed | No outcome recorded |
| Phase 4151 trials | ||||||
| Phase 4 | NCT07097493 Comparator | Aug → Dec 2026 expected | osteoarthritis, knee | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07620327 Comparator | Jun → Dec 2026 expected | — | Marmara University Pendik Training and Research Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07468604 Background | May 2026 → May 2027 expected | dysautonomia | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 4 | NCT07342010 Background | Feb 2026 → Feb 2027 expected | — | Nîmes University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07342413 Comparator | Feb → May 2026 overdue | vein disorder | Goldman, Butterwick, Fitzpatrick and Groff | Not yet recruiting | No outcome recorded |
| Show all 151 trials opens the full record — a long page | ||||||
| Phase not applicable127 trials | ||||||
| — | NCT07714915 Comparator | Jul → Aug 2026 overdue | dental pulp disorder | Recep Tayyip Erdogan University Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07338916 Background | Apr → Nov 2026 expected | — | Hospital del Trabajador de Santiago | Recruiting | No outcome recorded |
| — | NCT07638254 Background | Mar → Sep 2026 expected | pulpitis | Autonomous University of San Luis Potosí | Recruiting | No outcome recorded |
| — | NCT07144267 Comparator | Mar 2026 → Dec 2027 expected | — | Mansoura University | Not yet recruiting | No outcome recorded |
| — | NCT07408414 Comparator | Sep 2025 → Sep 2026 expected | pilonidal sinus | Opća županijska bolnica Požega | Recruiting | No outcome recorded |
| Show all 127 trials opens the full record — a long page | ||||||
Press releases naming this drug 23 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-05 | ALK-Abelló A/S | Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada alk.net ↗ |
| 2026-06-15 | ALK-Abelló A/S | EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis alk.net ↗ |
| 2026-06-11 | ALK-Abelló A/S | Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap alk.net ↗ |
| 2026-06-04 | ALK-Abelló A/S | ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026 alk.net ↗ |
| 2026-04-15 | ALK-Abelló A/S | neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada alk.net ↗ |
| 2026-03-31 | ALK-Abelló A/S | EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis alk.net ↗ |
| 2026-03-04 | ALK-Abelló A/S | New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors alk.net ↗ |
| 2026-02-15 | CSL Behring | neffy, adrenaline nasal spray, now approved to treat anaphylaxis in Australia csl.com ↗ |
| 2025-09-08 | ALK-Abelló A/S | Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray alk.net ↗ |
| 2025-06-26 | ALK-Abelló A/S | First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany alk.net ↗ |
| 2025-06-16 | ALK-Abelló A/S | ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 alk.net ↗ |
| 2025-06-13 | ALK-Abelló A/S | EURneffy® adrenaline nasal spray data demonstrating a pharmacological response comparable to intramuscular adrenaline injection in patients with allergic rhinitis presented at EAACI 2025 alk.net ↗ |
| 2025-05-02 | ALK-Abelló A/S | ALK enters into neffy® co-promotion agreement in the USA alk.net ↗ |
| 2024-11-09 | ALK-Abelló A/S | ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) alk.net ↗ |
| 2024-05-01 | CSL Behring | CSL Seqirus and ARS Pharma sign agreement to commercialise neffy™ (adrenaline nasal spray) in Australia and New Zealand csl.com ↗ |
| 2021-07-30 | ALK-Abelló A/S | ALK and Grandpharma team up to market the first adrenaline autoinjector in China alk.net ↗ |
| 2021-06-23 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action viatris.com ↗ |
| 2020-12-18 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi viatris.com ↗ |
| 2019-08-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States tevapharm.com ↗ |
| 2019-08-09 | ALK-Abelló A/S | ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA alk.net ↗ |
| 2011-09-06 | ALK-Abelló A/S | ALK launches new, improved adrenaline pen, Jext® in Europe alk.net ↗ |
| 2010-10-13 | ALK-Abelló A/S | ALK's new and improved adrenaline pen, JEXT®, approved in Europe alk.net ↗ |
| 2010-10-07 | ALK-Abelló A/S | ALK introduces new, improved adrenaline pen, JEXT® alk.net ↗ |
Evidence & citations 90 cited values
Every value below carries the sentence it was read from. 612 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epinephrine | “The purpose of this study was to investigate and compare pulpal anesthesia and cardiovascular parameters obtained with 0.6 ml of 4% articaine with epinephrine (1:100.000) for...” NCT03225326 ↗497“To investigate the role of adrenaline (epinephrine) in this response, we measured the inflammatory effects of adrenaline in a concentration and timeframe comparable to that...” PMID 41611977 ↗ Jan 2026 “Under steady state 0.2 ml kg(-1) and after 10 min 0.4 ml kg(-1) of one of the following three test solutions was administered i.v.: bupivacaine 0.125% (Group 1), bupivacaine...” PMID 19915187 ↗ Jan 2010 “The pain cocktail includes three medications: ropivacaine (a local anesthetic), ketorolac (an anti-inflammatory medication), and epinephrine (a medication to constrict blood...” NCT04074265 ↗ “The addition of adrenaline (epinephrine) 1:80 000 to lignocaine 2 % is considered the gold-standard regimen because it prolongs pulpal anaesthesia, reduces peak plasma...” NCT07633106 ↗ “The "Control Arm" will receive an adductor canal catheter through which they will receive a 20 ml bolus of 0.25% bupivacaine with 1:400,000 epinephrine followed by an adductor...” NCT02991404 ↗ “A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL...” NCT03860974 ↗ “Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made...” NCT01667445 ↗ “A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the...” NCT02682498 ↗ “Patients in group 2 received an adductor canal block with 30 mL of ropivacaine 0.5% with 1:400,000 epinephrine, whereas patients in group 3 received the adductor canal block...” PMID 29315129 ↗ Feb 2018 “The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to...” NCT02784041 ↗ “Epinephrine are prepared in 100 ml isotone saline solution according to weight and infused in 3 different infusion rates: 10 ng∙kg-1∙min-1, 25 ng∙kg-1∙min-1 and 50...” NCT05095259 ↗ “Tumescent solution prepared with 500 mL normal saline, 20 mL 2% lidocaine, one ampule of epinephrine (1 mg/mL), and 5 mL sodium bicarbonate; infiltrated into the operative...” NCT07408414 ↗ “periarticular injection of 50 ml solution which contains ropivacaine 15 mg, epinephrine 0.3 mg, cefmetazole 1000mg, ketorolac 30 mg and morphine HCL 10mg before closure of...” NCT01112436 ↗ “The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.” NCT02893384 ↗ “Guidelines recommend intramuscular injection of 500 μg adrenaline (epinephrine) for anaphylaxis in teenagers and adults; however, most autoinjectors deliver a maximum 300 μg dose.” PMID 36794963 ↗ Feb 2023 “tumescent formulation of cefazolin (1gm) and metronidazole (500mg/100ml) in a dilute solution of lidocaine (1gm), epinephrine (1mg) in 100ml and sodium bicarbonate (10mEq/10ml)” NCT03226626 ↗ “experimental group (periarticular injection of bupivacaine, ketorolac, morphine, and epinephrine in saline; 80cc plus 1.3% liposomal bupivacaine 20cc; total injection 100cc).” PMID 28478185 ↗ Apr 2017 “Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management.” NCT05492968 ↗ “A mixture of epinephrine 1:200,000 and lidocaine 1%). Buffered to reduce injection pain by 1 ml of sodium bicarbonate 8.4% for every 10 ml of the local anesthetic mixture.” NCT07000058 ↗ “Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml” NCT06113497 ↗ “Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml.” NCT02026687 ↗ “receive the Twin block local anesthetic (using the standard dental anesthetic 1.8 cc 2% lidocaine with 1:100,000 epinephrine), once, on the side/s of their extraction/s” NCT04414917 ↗ “The initial volume is 12 mL of bupivacaine 0.5% with epinephrine (5 µg/mL), with subsequent volumes adjusted in 2 mL increments based on the prior patient's response.” NCT07338916 ↗ “The knee joint capsule, periarticular and subcutaneous tissues will be infiltrated with 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline.” NCT04258241 ↗ “All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.” NCT05144828 ↗ “Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars” NCT05793905 ↗ “Pre-extubation local infiltration of 0.5% bupivacaine with epinephrine was administered at the surgical sites in addition to standard perioperative care” NCT07518225 ↗ “20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block” NCT03887650 ↗ “Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine” NCT00869037 ↗ “postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml” NCT01513564 ↗ “1 mL of 2% lidocaine with epinephrine was delivered via buccal infiltration using a conventional aspirating syringe and 27-gauge short needle.” NCT06992193 ↗ “Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.” NCT06499181 ↗ “The local anesthetic group will be injected with ropivacaine 2mg/mL (3mg/kg), epinephrine 1mg/mL (0.5mg), and ketorolac 30mg/mL (0.5mg/kg).” NCT06189781 ↗ “30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will be injected on both sides of the mid-abdomen posterior to the mid-axillary line.” NCT03794882 ↗ “The local anesthetic used in the study will be 2% lidocaine with 1:100,000 ppm epinephrine, part of the amide family of local anesthetics” NCT01622296 ↗ “TLA consists of a dilute solution of lidocaine (1gm/L), epinephrine (1mg/L) and sodium bicarbonate (10mEq/L) in 0.9% physiologic saline.” NCT02503904 ↗ “The dental local anesthetic (2% lidocaine with 1:100,000 epinephrine) will be delivered as the Temporo-masseteric Nerve Block injection.” NCT07094542 ↗ “epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery” NCT05051150 ↗ “20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.” NCT01479270 ↗ “The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block” NCT04263064 ↗ “Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine.” NCT03388814 ↗ “Female patients in this group will receive a 5 ml PIEB every 60 minutes of bupivacaine 0,05% + fentanyl 2mcg/ml + epinephrine 2mcg/ml.” NCT05534945 ↗ “8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.” NCT01405768 ↗ “Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.” NCT02256553 ↗ “Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.” NCT03845894 ↗ “Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL.” NCT00487084 ↗ “bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline” NCT00492973 ↗ “Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.” NCT01534416 ↗ “After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region.” NCT03279757 ↗ “A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.” NCT05152901 ↗ “Arm I: Intratumoral Chemotherapy. Cisplatin (NSC-119875) and Epinephrine in a bovine collagen gel, MP 5010, CDDP-e TI.” NCT00002659 ↗ “The lidocaine-based solution used for local anesthesia of the TM is Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine).” NCT03197558 ↗ “Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg” NCT05191745 ↗ “From periarticular injection consisted of 400 mg ropivacaine, 5 mg morphine and 0.4 mg epinephrine in 50 cc solution.” NCT06557018 ↗ “Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.” NCT02246179 ↗ “1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)” NCT01606969 ↗ “This study is designed to evaluate the pharmacokinetics (PK) of epinephrine administered as a single dose of DESF.” NCT07703982 ↗ “In the application, a 22G 10 cm needle is used in the form of 20 ml 0.25% bupivacaine + 2.0 μg/mL of epinephrine.” NCT05943080 ↗ “Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.” NCT03549234 ↗ “1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control” NCT06345833 ↗ “4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%” NCT01611324 ↗ “30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.” NCT05996133 ↗ “The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.” NCT02619409 ↗ “A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.” NCT03408184 ↗ “and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries)” NCT05806307 ↗ “The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.” NCT04019834 ↗ “injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process” NCT03476642 ↗ “Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.” NCT02369523 ↗ “solution containing sterile, cooled 0.9% sodium chloride and 1% lidocaine with epinephrine (1:100,000)” NCT06820164 ↗ “Bupivacaine, Dexamethasone, Epinephrine for hernia patients receiving abdominal wall reconstruction” NCT07518238 ↗ “A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).” NCT03600454 ↗ “A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance” NCT05118620 ↗ “Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.” NCT02269735 ↗ “2% lidocaine with 1:100,000 epinephrine is the standard dental local anesthetic in universal use.” NCT04880707 ↗ “Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.” NCT01005459 ↗ “For the patient who did not response to high dose norepinephrine, epinephrine was recommended.” NCT04339868 ↗ “After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine” NCT02831374 ↗ “0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.” NCT03243032 ↗ “wetting fluid will be used (1000 ml normal saline, 20 ml lidocaine 2%, and 1 mg epinephrine)” NCT04425447 ↗ “Epinephrine 1mg (1mL), 0.5% ropivacaine (60mL), Acetaminophen 1000mg IV, Toradol 30mg (1ml)” NCT06113211 ↗ “Standard single-shot anesthesia consists of bupivacaine 0.25% with epinephrine 1:400,000.” NCT05019638 ↗ “using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine” NCT05335070 ↗ “5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).” NCT05037812 ↗ “Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml)” NCT02571283 ↗ “Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)” NCT01898052 ↗ “preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.” NCT02409498 ↗ “adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine” NCT03530280 ↗ “A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.” NCT06532162 ↗ “Intrafascial injection of clonidine, epinephrine, ropivacaine, and toradol solution” NCT06935331 ↗ “a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected” NCT03408483 ↗ “500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)” NCT03282929 ↗ “10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate” NCT04833777 ↗ “1% lidocaine with 1:100,000 epinephrine injected directly into operative site.” NCT03135340 ↗ “IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.” NCT04822415 ↗ “20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine” NCT02741713 ↗ “Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml” NCT05834023 ↗ “20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection” NCT02379221 ↗ “Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.” NCT04493528 ↗ “This spray consists of lidocaine hydrochloride-epinephrine hydrochloride” NCT03140787 ↗ “Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)” NCT02371759 ↗ “US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine” NCT01133730 ↗ “Infiltration of lidocaine 1% with 1:100,000 epinephrine (maximum 10cc)” NCT05300685 ↗ “Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only” NCT03317197 ↗ “0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL” NCT03780478 ↗ “using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution” NCT04888858 ↗ “bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.” NCT03420638 ↗ “300 micrograms of adrenaline (epinephrine Braun Medical SA Spain)” NCT05248724 ↗ “4% Articaine HCL with 1:1000000 epinephrine Anaesthetic carpule” NCT05473819 ↗ “Femoral Nerve Block with 40ml bupivacaine plus 0.5% epinephrine” NCT01911949 ↗ “Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine.” NCT05292677 ↗ “Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000” NCT05897385 ↗ “Injectable anesthesia 2% lidocaine with epinephrine 1:100.000” NCT01860235 ↗ “150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine” NCT02760043 ↗ “Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine” NCT03087604 ↗ “Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)” NCT01255709 ↗ “non-buffered LA, 2% lidocaine with epinephrine 1:100,000” NCT05757648 ↗ “300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran)” NCT05324995 ↗ “articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml” NCT02548533 ↗ “Articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml” NCT02938286 ↗ “using ropivacaine, epinephrine, ketorolac, and morphine” PMID 24706022 ↗ Jan 2015 “nebulized epinephrine mixed 3% saline and oral placebo” NCT01660867 ↗ “lidocaine hydrochloride 2% and epinephrine 1:100000” NCT04061265 ↗ “plus 0.5mg epinephrine made up to 100ml with saline” NCT01312415 ↗ “30ml of 0.35% ropivacaine with 1:400K epinephrine” NCT04860843 ↗ “1.8 mL of 2% lidocaine with 1:100,000 epinephrine” NCT01574807 ↗ “2% lidocaine with epinephrine 1: 100000 1.8 mL” NCT03176446 ↗ “Lidocaine 1% with Epinephrine 1:100,000 - 20ml” NCT03105674 ↗ “with bupivacaine, epinephrine and bicarbonate” NCT03867539 ↗ “0.25% bupivacaine with epinephrine 1:200 000.” NCT06945263 ↗ “0.25% bupivacaine with epinephrine 1:200,000” NCT03408340 ↗ “8 mL lidocaine 2% with epinephrine 5µg mL-1” NCT02534012 ↗ “PIFB done with bupivacaine and epinephrine” NCT05676814 ↗ “2% mepivacaine with 1:100,000 epinephrine” NCT01032798 ↗ “2% lidocaine with epinephrine (2.25 mL)” NCT04951128 ↗ “Lidocaine 1% with 1:100,000 epinephrine” NCT00578214 ↗ “with epinephrine at 1:200,000 (5 ug/mL)” NCT04034836 ↗ “Norepinephrine, dopamine, epinephrine” NCT03020407 ↗ “Lidocaine 2% with epinephrine 5mcg/ml” NCT02264795 ↗ “epinephrine (Adrenaline® 1mg/vial)” NCT06203847 ↗ “0.1mg epinephrine (1:200000)” NCT02838056 ↗ “0.5 mg epinephrine (1mg/ml)” NCT07151417 ↗ “300mcg (0.3mL) epinephrine” NCT05224089 ↗ “Lidocaine with epinephrine” NCT05267938 ↗ “1:1000 epinephrine (0.4ml)” NCT03914235 ↗ “Epinephrine 1mg/mL, 0.5mL” NCT03696199 ↗ “Epinephrine nasal spray” NCT06834165 ↗ “epinephrine” NCT05658692 ↗ “epinephrine” NCT01800877 ↗ “Epinephrine” NCT02197273 ↗ |
| Known as | (-)-(r)-epinephrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | [11C]-Epinephrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Adren co | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Adrenaclick | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Adrenalin | “Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively.” NCT04025606 ↗15“epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml” NCT02030717 ↗ “Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone” NCT02374008 ↗ “30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration” NCT03395912 ↗ |
| Known as | Adrenalin (epinephrine) | “Adrenalin (epinephrine)” NCT05037812 ↗1“Adrenalin (epinephrine)” NCT05019638 ↗ |
| Known as | Adrenalin tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | adrenaline | “20 ml of 0.5% bupivacaine added to them 50 μg adrenaline in a concentration of 1:400,000, were prepared by an assistant immediately before administration and injected in an...” NCT05381389 ↗105“Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de...” NCT05531435 ↗ “We compared the effects of dopexamine and norepinephrine (noradrenaline) with those of epinephrine (adrenaline) on gastric mucosal blood flow (GMBF) in patients with septic shock.” PMID 16507156 ↗ Feb 2006 “Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline” NCT03176758 ↗ “Guidelines recommend intramuscular injection of 500 μg adrenaline (epinephrine) for anaphylaxis in teenagers and adults; however, most autoinjectors deliver a maximum 300 μg dose.” PMID 36794963 ↗ Feb 2023 “Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).” NCT02644811 ↗ “Local injection of Mepivacaine (10 mg/ml) and adrenaline (5 mcg/ml) approximately 10 ml in the incisional area at least 10 minutes before surgery start.” NCT06172400 ↗ “ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side” NCT04531215 ↗ “Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000” NCT04919421 ↗ “Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.” NCT03913845 ↗ “Adrenaline is a potent vasoconstrictive agent that has a high risk of cardiovascular effects if an intravascular instillation is performed.” NCT05986266 ↗ “Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 10 to 20 mL, i.e. a total of 50 to 200 mg of lidocaine.” NCT05343299 ↗ “Epinephrine (adrenaline) is a substance produced by the body (in the adrenal gland) in response to stress such as infection or injury.” NCT00753402 ↗ “isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg” NCT03498092 ↗ “The investigator will add Sodium bicarbonate in lidocaine with adrenaline (1:80,000 ) for Buffered Local anesthesia.” NCT07592143 ↗ “Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.” NCT01442558 ↗ “injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000” NCT06490614 ↗ “(0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation)” NCT01560767 ↗ “bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml” NCT00805298 ↗ “2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline” NCT04850885 ↗ “a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline.” NCT03693820 ↗ “1ml 50% MgSO4 added to 0.375% Plain Ropivacaine plus 5 mcg/ml adrenaline for scalp block” NCT07075783 ↗ “1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle” NCT02619981 ↗ “Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline).” NCT01878864 ↗ “different concentrations of lidocaine with same concentration of adrenaline” NCT04692896 ↗ “Epinephrine, or adrenaline, is produced by our bodies in times of stress.” NCT00548886 ↗ “dopamine and / or dobutamine and / or milrinone and / or adrenaline” NCT01301313 ↗ “Articaine hydrochloride/epinephrine (adrenaline) hydrochloride” NCT03354312 ↗ “Group one received articaine 4% with 1:00.000 adrenaline.” NCT04236115 ↗ “Use of epinephrine/adrenaline solution 1:1000 topically” NCT04758728 ↗ “Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml” NCT01281891 ↗ “standard solution for injection including adrenaline” NCT05345613 ↗ “Adrenaline 100mcg in 500ml of ringers lactate” NCT03518463 ↗ “one block will contain 5 mcg/kg of adrenaline” NCT00523055 ↗ “Epinephrine (Adrenaline) bolus then infusion” NCT07480889 ↗ “Topical instillation of adrenaline up to 3x.” NCT04771923 ↗ “1:100,000 epinephrine (adrenaline)” NCT02807298 ↗ “epinephrine (Adrenaline® 1mg/vial)” NCT06203847 ↗ “Drug: Epinephrine (Adrenaline)” NCT07425678 ↗ “Adrenaline” NCT04432597 ↗ |
| Known as | Adrenaline (as tartrate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Adrenaline acid tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Adrenaline bitartate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Adrenalinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Ana-guard | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Ana-kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Anapen | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Anaphylactic shock drug kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Asma-vydrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Asthmahaler | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Auvi-q | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Bronitin | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Bronitin mist | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Bronkaid mist | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Brovon | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | DESF | “This study is designed to evaluate the pharmacokinetics (PK) of epinephrine administered as a single dose of DESF.” NCT07703982 ↗ |
| Known as | E004 | “This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), using a stable isotope deuterium-labeled...” NCT01188577 ↗2“E004 (epinephrine inhalation aerosol), 90 mcg/actuation” NCT01025648 ↗ “Experimental arm utilizing Epinephrine HFA-MDI (E004)” NCT01737905 ↗ |
| Known as | Emerade | “500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)” NCT03282929 ↗ |
| Known as | epi | “2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth” NCT03368391 ↗1“Lidocaine w/ Epi” NCT01243112 ↗ |
| Known as | Epi e z pen jr | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinefrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrin | “Drug: Epinephrin 0.03” NCT05051150 ↗ |
| Known as | epinephrine (adrenaline) hydrochloride | “Articaine hydrochloride/epinephrine (adrenaline) hydrochloride” NCT03354312 ↗ |
| Known as | Epinephrine (copackaged) | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine 1mg/ml - Pt. Pharos Tbk | “Epinephrine 1mg/ml - Pt. Pharos Tbk” NCT06789549 ↗ |
| Known as | Epinephrine Bitartrate | “Participants in this group received local anesthesia consisting of 2% mepivacaine hydrochloride with 1:55,000 (0.018 mg/mL) epinephrine bitartrate prior to simple mandibular...” NCT07013071 ↗ |
| Known as | Epinephrine bitartrate component of duranest | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine bitartrate component of lignospan forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine bitartrate component of orabloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine bitartrate component of sensorcaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine bitartrate component of septocaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine CFC-MDI | “A previously marketed Epinephrine CFC-MDI, labeled "For Investigational Use Only" will be used as a Reference Control (Arm C).” NCT01737892 ↗ |
| Known as | Epinephrine component of duranest | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine component of iontocaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine component of lidosite topical system kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine component of octocaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine d-bitartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | epinephrine Hcl | “and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries)” NCT05806307 ↗ |
| Known as | EPINEPHRINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine hydrogen tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrine Inhalation Aerosol - CFC | “Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation” NCT01737892 ↗ |
| Known as | Epinephrine Inhalation Solution | “Drug: Epinephrine Inhalation Solution” NCT05006235 ↗ |
| Known as | Epinephrine Injection | “Drug: Epinephrine Injection” NCT05166343 ↗ |
| Known as | Epinephrine tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrini hydrogenotartras | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epinephrinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epipen | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epipen e z pen | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Epipen jr | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Eppy | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Glauposine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Gppe inh soln | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Jext | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | L-Epinephrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01276821 ↗ |
| Known as | L-epinephrine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | L-epinephrine hydrogen tartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Levogira | “dexamethasone and epinephrine (Levogira) (ED)” NCT02585531 ↗ |
| Known as | Medihaler-epi | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Neffy | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Nephridine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | NSC-62786 | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | NSC-756755 | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Primatene mist | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Racepinefrine hydrochloride, (r)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Racepinefrine, (r)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Riddobron | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Riddofan | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Rybarvin | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Simplene | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Soln made to rybarvin for | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Sus-phrine | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Sus-phrine sulfite free | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Sus-phrine sulphite-free | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Symjepi | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Tonogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Twinject | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Twinject 0.15 | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Known as | Twinject 0.3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL679 ↗ |
| Action | Activate | “epinephrine, is an alpha- and beta- adrenergic agonist” NCT02371759 ↗ |
| Modality | Other / unclassified | “In septic shock, when volume resuscitation fails to restore mean arterial pressure, catecholamines such as dopamine, dobutamine, epinephrine, or norepinephrine are used, either...” NCT00134212 ↗ |
| Route | Other | “intratumoral injection of a cisplatin/epinephrine gel (CDDP-e TI)” NCT00002659 ↗ |